Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.72 |
| ▸ | APP | P05067 | 7/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.72 |
| ▸ | NPC1 | O15118 | 6/20 | 0.72 |
| ▸ | RAB9A | P51151 | 6/20 | 0.72 |
| ▸ | GAA | P10253 | 5/20 | 0.72 |
| ▸ | GLA | P06280 | 4/20 | 0.72 |
| ▸ | SNCA | P37840 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | CASP3 | P42574 | 1/20 | 0.58 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.58 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.58 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 5/20 | 0.56 |
| ▸ | RORC | P51449 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12422217 | 0.90 | MAPT (0.81) | MAPTAPPKDM4ENPC1RAB9A | |
| SCHEMBL10605601 | 0.86 | MAPT (0.63) | MAPTAPPKDM4ENPC1RAB9A | |
| SCHEMBL12619483 | 0.84 | MAPT (0.73) | MAPTAPPKDM4ENPC1RAB9A | |
| SCHEMBL2950103 | 0.84 | APP (0.72) | MAPTAPPKDM4ENPC1RAB9A | |
| SCHEMBL492713 | 0.84 | APP (1.00) | MAPTAPPKDM4ENPC1RAB9A | |
| SCHEMBL13453290 | 0.84 | APP (1.00) | MAPTAPPKDM4ENPC1RAB9A | |
| SCHEMBL5349180 | 0.84 | MAPT (0.72) | MAPTAPPKDM4ENPC1RAB9A | |
| SCHEMBL2244143 | 0.84 | APP (0.72) | MAPTAPPKDM4ENPC1RAB9A | |
| SCHEMBL507097 | 0.83 | MAPT (0.71) | MAPTAPPKDM4ENPC1RAB9A | |
| SCHEMBL6483615 | 0.83 | MAPT (0.73) | MAPTAPPKDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103073520-B | Method for synthesizing 2-phenyl benzothiazole and derivative thereof | HUNAN UNIVERSITY (CN) | 2014-10-08 | — | — | CN | disclosed |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-16 | — | — | US | disclosed |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-09 | — | — | US | disclosed |
| US-8501713-B2 | Drug combinations for the treatment of duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-06 | — | — | US | disclosed |
| CN-103073520-A | Method for synthesizing 2-phenyl benzothiazole and derivative thereof | UNIV HUNAN | 2013-05-01 | — | — | CN | disclosed |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | SUMMIT (OXFORD) LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | PYGM, CPT1B, GYS1 | MAPT 3113/4885APP 4017/4885KDM4E 3311/4885 |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | PYGM, CPT1B, GYS1 | MAPT 3113/4885APP 4017/4885KDM4E 3311/4885 |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | MAPT 4858/4885APP 4337/4885KDM4E 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.